

The Prevalence of Shiga toxin-1 in *Shigella* spp. Isolates Collected from Diarrhea Patients, Ahvaz, Iran

Nahid Mahdian

Ilam University of Medical Sciences

Ali Gheysarzadeh

Ilam University of Medical Sciences

Hassan Valadbeigi

Ilam University of Medical Sciences

Abbas Maleki

Ilam University of Medical Sciences

Norkhoda Sadeghifard (✉ Sadeghiifard@gmail.com)

Ilam University of Medical Sciences

Research

Keywords: Shigella, Toxin, *S. flexneri*, *S. sonnei*, *S. boydii*, Stx1

Posted Date: February 12th, 2020

DOI: <https://doi.org/10.21203/rs.2.23292/v1>

License:  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Objective

Shigellosis as one of the substantial causative agents of microbial dysentery still has a remarkable prevalence in areas with poor hygienic infrastructures. The probable existence of the deadly Shiga toxin-1 (Stx1) in some *Shigella* strains would manifest life-threatening clinical symptoms of the infection. The aim of this study was to determine the presence of Stx1 in isolated from patients with diarrhea.

Results

Totally, 227 *Shigella* species including 60 *S. flexneri*, 157 *S. sonnei*, and 10 *S. boydii* were collected from diarrheal patients in tropical infectious diseases research center of Ahvaz, Iran, from 2013 to 2015. The isolates were collected mostly from the intensive care unit, infectious disease, and surgery department. The isolates were identified and the polymerase chain reaction (PCR) was performed to detect the *stx* gene. The results indicated that none of them encode the *stx* gene. In conclusion, isolates of this study were not capable of *stx1* encoding.

1. Introduction

Shigella is a gram-negative, non-motile bacillus which serves as a major enteropathogen. *Shigella* infections mostly have been associated with watery diarrhea, dysentery, as well as some severe complications such as encephalopathy (1). This type of bacteria has four species including *S. flexneri*, *S. sonnei*, and *S. boydii*. These species are distributed worldwide. For instance, *S. flexneri* has been reported to high prevalence in India and Rwanda, while *S. sonnei* was commonly distributed in Thailand, Israel, and the USA (2-6). *Shigella* species is mainly diagnosed based on some symptoms such as fever, blood, mucous diarrhea and abdominal pain. Routine microscopy of fresh stool is a simple, cheap, rapid, and easy test to detect *Shigella* infections (7). For the treatment of diagnosed *Shigella* infections, ciprofloxacin is the first-line and pivmecillinam, ceftriaxone or azithromycin are the second-lines of treatment (8).

Shiga toxin (Stx) as a potent bacterial toxin was initially founded in *S. dysenteriae* and after that, it also was founded in *Escherichia coli*. Stx at least has two types including Stx1 and Stx2. Despite diverse genetically and immunologically origins, they have the same mechanism of action. Structural analysis indicated that Stxs consist of two major subunits including catalytic domains (A) and binding domain (B) to make an AB₅ complex inhibiting eukaryotic protein synthesis (9). In addition, this toxin has also been shown to trigger cytokine production and induce host cell apoptosis (10). Stx toxicity is responsible for severe human disorders such as hemorrhagic colitis and hemolytic uremic syndrome (11).

The gene encoding Stx in *S. dysenteriae* is located on its chromosome but this gene in *E. coli* is associated to be a prophage (9). However, recently it has been shown that Stx-converting phages are capable of transferring *stx* genes from cell to cell through a transduction process called horizontal gene

transferring. The exact mechanism underlying such gene transferring is partially unknown however, it has been suggested that after infection with a Stx-converting phage, the integrated *stx* genes mostly remain silent in the lysogens. In the presence of DNA damaging agents or other factors that induce the bacterial S.O.S. response, the lytic cycle was activated. Infected cell lysis eventually resulted in the releasing of phage particles that enhance *stx* genes transferring to other bacteria (12, 13). A growing body of evidence indicated that the *stx* gene has the potential to be transferred to other Shigella species like *S. flexneri*, *S. sonnei*, and *S. boydii* but with a rare prevalence (14-16). Therefore, the presence of *stx* genes is one of the most important challenges in clinical microbiology. Here, we identified 227 Shigella isolates including 60 *S. flexneri*, 157 *S. sonnei* and 10 *S. boydii* which all have the potentials to encode *stx1*. The PCR analyses determined that none of the samples encodes *stx1*.

2. Materials And Methods

2.1.1 Sampling, isolation, and identification

The specimens (N=227) were collected between January 2013 to October 2015 from patients with diarrhea in the infectious and tropical diseases research center of Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. The patients were characterized by 3 episodes of diarrhea with or without blood, mucus, and gastric cramps. For bacterial isolation, the specimens were cultured in Brain Heart Infusion agar followed by biochemical tests including oxidase, urease, Triple Sugar Iron agar (TSI), motility, and carbohydrate fermentation. The isolates were consists of 60 *S. flexneri*, 157 *S. sonnei*, and 10 *S. boydii*.

2.1.2 DNA extraction and molecular identification

DNA of Shigella species isolates was extracted using the boiling method as described previously. In brief, three bacterial colonies were dissolved in 1000 µl of LB (Luria Broth) medium. The samples were placed in boiling water for 10 min followed by incubation in -20 °C for 10 min. This freeze-thaw cycle was repeated again followed by centrifugation at 10,000 rpm for 5 min. The supernatant was then discarded and the pellets were dissolved in ethanol. The samples were finally air-dried followed by dissolving in distilled water and storing in -20 °C until PCR examination.

2.1.3 PCR analysis

The PCR analysis was performed similarly to the previous study(17). The extracted DNA was subjected to PCR using the following primers according to manufactures instruction. Forward *stx1*: 5' CTG TGG CAA GAG CGA TGT TA 3', Reverse *stx1*:5' GCC GGA CAC ATA GAA GGA AA 3'. In order to perform PCR analysis, 12 µL of PCR master mix 8 µL of sterile distilled water, 2 µL reverse and forward primers (15 Picomole of each one) and 3 µL of extracted DNA (50 Nanogram/ml) were added to each vial. The PCR procedures were as follow; the initial denaturation at 95°C for 5 minutes, 35 cycles at 95°C for one min, annealing at 55°C for one min, extension at 72°C for 30 seconds, and a final extension at 72°C for 10 min.

The PCR products were finally subjected to gel electrophoresis on 2% agarose followed by ethidium bromide visualization.

3. Result And Discussion

PCR analysis was performed to investigate the presence of *stx1* gene. *S. dysenteriae* was also used as a positive control (RITCC1875). As indicated in Fig. 1, our data revealed that all 227 isolates were negative for the *stx1* gene. This is the only prospective study incorporating molecular methods for the specific detection of *stx* genes in stools diarrhea patients in Iran. No prevalence of *stx* in patients of this study is in parallel with low rates in other countries. The infections caused by *Shigella* species are globally distributed and prevalent in developing countries such as Bangladesh, and Afghanistan (18, 19). However, it has been shown that infection with *Shigella* species is prevalent in Iran (20).

To date, infections with *Stx*-producing organisms in Iran are generally caused by *Escherichia coli* (21, 22). On the other hand, it has been reported that more than 70 percent of shigellosis are caused by *S. sonnei* however, *S. dysenteriae* infections as the main source of *Stx-1* among *Shigella* species, are rare (23). In addition, other species such as *Enterobacter cloacae*, *Citrobacter freundii*, *Aeromonas hydrophila* and *Aeromonas caviae* as well as some species of *E. coli* have been suggested to encode *stx* gene (24, 25). The presence of the *stx* gene in such bacteria supporting the hypothesis of horizontal gene transferring. In addition, the study of Gray et al further confirmed that new *stx*-encoding prophages were circulating within geographical area, and they spread to other continents, by immigrants (26).

4. Limitation

The aim of this study was to determine the prevalence of *stx1* gene in *Shigella* isolates and, if available, to the cytotoxicity of positive isolates on the cells were supposed to be evaluated. However, we did not find any positive isolates for the *stx1* gene in this study. As the main limitation, indeed this study was not enough to introduce Iran as a country without strains of *stx1* coding species. This achievement requires further studies, especially in areas where bacteria *Shigella* are endemic. In addition, due to phage transferring probability to other bacteria such as *Enterobacter* and *Aeromonas* other bacteria can be tested to evaluate the presence *stx1* gene.

5. Conclusion

The aim of this study was to determine the prevalence of *stx1* gene in *Shigella* isolates and, if available, to the cytotoxicity of positive isolates on vero cells were supposed to be evaluated. However, we did not find any positive isolates for the *stx1* gene in this study. Indeed this study was not enough to introduce Iran as a country without strains of *stx1* coding species. This achievement requires further studies, especially in areas where bacteria *Shigella* are endemic. In addition, due to phage transferring probability to other bacteria such as *Enterobacter* and *Aeromonas* other bacteria can be tested to evaluate the presence *stx1* gene.

Abbreviations

Stx1: Shiga toxin-1

PCR: polymerase chain reaction

TSI: Triple Sugar Iron

LB: Luria Broth

Declarations

Acknowledgment

The authors appreciate Dr. Iraj Pakzad for his technical supports.

Funding

This study was financially supported by the Ilam University of Medical Sciences, Ilam, I.R. Iran.

Competing interests

The authors declare that there is no conflict of interests in the publication of this study.

Ethics approval and consent to participate

The Ethics issues of this study were approved by the ethics committee of Ilam University of Medical Sciences. The written informed consent was obtained from all the participants, and informed consent obtained was written.

Availability of data and materials

The source of data is available on request to the corresponding author

Authors' Contributions

N.M designed and performed the experiments, analyzed data, and wrote the manuscript. **H.V** designed and performed experiments. **A.Gh** and **A.M** designed experiments, analyzed data, and wrote the manuscript. **N.S** designed the study, analyzed data, and wrote the manuscript. All authors read and approved the final manuscript.

Consent for publication

Not applicable.

References

1. Lima IF, Havt A, Lima AA. Update on molecular epidemiology of Shigella infection. *Current opinion in gastroenterology*. 2015;31(1):30-7.
2. Dutta S, Rajendran K, Roy S, Chatterjee A, Dutta P, Nair G, et al. Shifting serotypes, plasmid profile analysis and antimicrobial resistance pattern of shigellae strains isolated from Kolkata, India during 1995–2000. *Epidemiology & Infection*. 2002;129(2):235-43.
3. Bogaerts J, Verhaegen J, Munyabikali JP, Mukantabana B, Lemmens P, Vandeven J, et al. Antimicrobial resistance and serotypes of Shigella isolates in Kigali, Rwanda (1983 to 1993): increasing frequency of multiple resistance. *Diagnostic microbiology and infectious disease*. 1997;28(4):165-71.
4. Von Seidlein L, Kim DR, Ali M, Lee H, Wang X, Thiem VD, et al. A multicentre study of Shigella diarrhoea in six Asian countries: disease burden, clinical manifestations, and microbiology. *PLoS medicine*. 2006;3(9):e353.
5. Mates A, Eyny D, Philo S. Antimicrobial resistance trends in Shigella serogroups isolated in Israel, 1990–1995. *European Journal of Clinical Microbiology and Infectious Diseases*. 2000;19(2):108-11.
6. Shiferaw B, Shallow S, Marcus R, Segler S, Soderlund D, Hardnett FP, et al. Trends in population-based active surveillance for shigellosis and demographic variability in FoodNet sites, 1996–1999. *Clinical infectious diseases*. 2004;38(Supplement_3):S175-S80.
7. Nave HH, Mansouri S, Sadeghi A, Moradi M. Molecular diagnosis and anti-microbial resistance patterns among Shigella spp. isolated from patients with diarrhea. *Gastroenterology and hepatology from bed to bench*. 2016;9(3):205.
8. Brown JD, Willcox SJ, Franklin N, Hazelton B, Howard P, Reinten T, et al. Shigella species epidemiology and antimicrobial susceptibility: the implications of emerging azithromycin resistance for guiding treatment, guidelines and breakpoints. *Journal of Antimicrobial Chemotherapy*. 2017;72(11):3181-6.
9. Amani J, Ahmadpour A, Fooladi AAI, Nazarian S. Detection of E. coli O157: H7 and Shigella dysenteriae toxins in clinical samples by PCR-ELISA. *Brazilian Journal of Infectious Diseases*. 2015;19(3):278-84.
10. Foster GH, Tesh VL. Shiga toxin 1-induced activation of c-Jun NH2-terminal kinase and p38 in the human monocytic cell line THP-1: possible involvement in the production of TNF- α . *Journal of leukocyte biology*. 2002;71(1):107-14.
11. Krüger A, Lucchesi PM. Shiga toxins and stx phages: highly diverse entities. *Microbiology*. 2015;161(3):451-62.
12. Khalil RK, Skinner C, Patfield S, He X. Phage-mediated Shiga toxin (Stx) horizontal gene transfer and expression in non-Shiga toxigenic Enterobacter and Escherichia coli strains. *Pathogens and disease*. 2016;74(5).
13. Hallewell J. Shiga toxin-producing bacteriophage in Escherichia coli O157: H7: Lethbridge, Alta.: University of Lethbridge, Department of Biochemistry, 2008; 2008.

14. Beutin L, Strauch E, Fischer I. Isolation of *Shigella sonnei* lysogenic for a bacteriophage encoding gene for production of Shiga toxin. *The Lancet*. 1999;353(9163):1498.
15. Fogolari M, Mavian C, Angeletti S, Salemi M, Lampel KA, Aurelli AT. Distribution and characterization of Shiga toxin converting temperate phages carried by *Shigella flexneri* in Hispaniola. *Infection, Genetics and Evolution*. 2018;65:321-8.
16. Kotloff KL, Riddle MS, Platts-Mills JA, Pavlinac P, Zaidi AK. Shigellosis. *The Lancet*. 2018;391(10122):801-12.
17. Valadbeigi H, Tabatabaei RR, Malek A, Sekawi Z, Raftari M, Parvaneh K, et al. Genomic diversity and virulence genes among clinical isolates of *Pseudomonas aeruginosa*. *Clin Lab*. 2014;60(1):363-7.
18. Wallace MR, Hale BR, Utz GC, Olson PE, Earhart KC, Thornton SA, et al. Endemic infectious diseases of Afghanistan. *Clinical Infectious Diseases*. 2002;34(Supplement_5):S171-S207.
19. George CM, Ahmed S, Talukder KA, Azmi IJ, Perin J, Sack RB, et al. *Shigella* infections in household contacts of pediatric shigellosis patients in rural Bangladesh. *Emerging infectious diseases*. 2015;21(11):2006.
20. Yaghoubi S, Ranjbar R, Dallal MMS, Fard SY, Shirazi MH, Mahmoudi M. Profiling of virulence-associated factors in *Shigella* species isolated from acute pediatric diarrheal samples in Tehran, Iran. *Osong public health and research perspectives*. 2017;8(3):220.
21. Hooman N, Mansour-Ghanaei R, Yaghoubi M, Nakhaie S. The Prevalence of Shiga toxin-producing *Escherichia coli* in Patients with Gastroenteritis and Sources of Infections in Iran: A Systematic Review Study Protocol. *Journal of Pediatric Nephrology*. 2016;4(3):82-5.
22. Ranjbar R, Masoudimanesh M, Dehkordi FS, Jonaidi-Jafari N, Rahimi E. Shiga (Vero)-toxin producing *Escherichia coli* isolated from the hospital foods; virulence factors, o-serogroups and antimicrobial resistance properties. *Antimicrobial Resistance & Infection Control*. 2017;6(1):4.
23. Lamba K, Nelson JA, Kimura AC, Poe A, Collins J, Kao AS, et al. Shiga Toxin 1–Producing *Shigella sonnei* Infections, California, United States, 2014–2015. *Emerging infectious diseases*. 2016;22(4):679.
24. Probert WS, McQuaid C, Schrader K. Isolation and identification of an *Enterobacter cloacae* strain producing a novel subtype of Shiga toxin type 1. *Journal of clinical microbiology*. 2014;52(7):2346-51.
25. Herold S, Karch H, Schmidt H. Shiga toxin-encoding bacteriophages–genomes in motion. *International journal of medical microbiology*. 2004;294(2-3):115-21.
26. Gray MD, Lacher DW, Leonard SR, Abbott J, Zhao S, Lampel KA, et al. Prevalence of Shiga toxin-producing *Shigella* species isolated from French travellers returning from the Caribbean: an emerging pathogen with international implications. *Clinical Microbiology and Infection*. 2015;21(8):765. e9-e14.

Figures



Figure 1

The representative image of PCR product for *stx1* gene. Lane 1 was positive control of *S. dysenteriae*, Lane 2 was negative control, Lane 3, 4 and 5 were *S. sonnei*, Lane 6, 7 and 8 were *S. flexneri*, and Lane 9 was *S. boydii*